SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Lucid Group, Inc. manufactures electric vehicles. It designs, develops, and builds energy storage systems for electric vehicles and supplies automakers with the battery pack system needed to power hybrid, plug-in, and electric vehicles. The company was founded in December 2007 and is headquartered in Newark, CA.

Lucid Group Inc

Lucid is experiencing extreme volatility and intense community discussion following a dramatic sell-off triggered by unverified bankruptcy rumors that the company has since formally denied. Traders are currently debating whether this price action constitutes a massive short squeeze setup or a manipulation tactic, while investors look for further clarity on the company's liquidity and operational trajectory.

Taiwan Semiconductor Manufacturing Co., Ltd. engages in the manufacture and sale of integrated circuits and wafer semiconductor devices. Its chips are used in personal computers and peripheral products, information applications, wired and wireless communications systems products, and automotive and industrial equipment including consumer electronics such as smartphones, digital television, game consoles, and digital cameras. The company was founded by Chung Mou Chang on February 21, 1987 and is headquartered in Hsinchu, Taiwan.

Taiwan Semiconductor Manufacturing - ADR

TSM is trending following a record-setting Q2 earnings report that beat analyst expectations and showcased 36% year-over-year revenue growth, fueled by relentless demand for high-performance computing and AI-driven chips. While the stock has faced near-term volatility and profit-taking, the community remains intensely focused on its massive $100 billion expansion in Arizona and its long-term outlook as the backbone of the global AI infrastructure buildout.

Rocket Lab Corp. engages in the development of rocket launch and control systems for the space and defense industries. It operates through the Launch Services and Space Systems segments. The Launch Services segment provides launch services to customers on a dedicated mission or ride-share basis. The Space Systems segment consists of spacecraft engineering and design services, spacecraft components, spacecraft manufacturing, and on-orbit mission operations. The company was founded by Peter Beck in 2006 and is headquartered in Long Beach, CA.

Rocket Lab Corp.

Rocket Lab USA Inc

Rocket Lab is currently trending as investors debate the impact of broader sector volatility, particularly the recent performance of major industry players, while weighing long-term catalysts like Neutron development against immediate technical drawdowns. Community sentiment is deeply divided between those viewing the current price as a generational buying opportunity and traders expressing frustration over relentless selling pressure.

UnitedHealth Group, Inc. engages in the provision of health care coverage, software, and data consultancy services. It operates through the following segments: UnitedHealthcare, OptumHealth, OptumInsight, and OptumRx. The UnitedHealthcare segment utilizes Optum's capabilities to help coordinate patient care, improve affordability of medical care, analyze cost trends, manage pharmacy benefits, work with care providers more effectively, and create a simpler consumer experience. The OptumHealth segment provides health and wellness care, serving the broad health care marketplace including payers, care providers, employers, government, life sciences companies, and consumers. The OptumInsight segment focuses on data and analytics, technology, and information to help major participants in the healthcare industry. The OptumRx segment offers pharmacy care services. The company was founded by Richard T. Burke in January 1977 and is headquartered in Eden Prairie, MN.

Unitedhealth Group Inc

UnitedHealth Group is seeing increased investor activity and bullish momentum driven by a strong earnings report that topped consensus expectations and included upwardly revised guidance. Market participants are actively discussing the stock's role as a sector leader and defensive compounder, with many focusing on whether recent institutional accumulation and improved medical care ratios signal a sustained path back toward previous highs.

Oracle Corporation. The Group's principal activities are to develop, manufacture, market, distribute and service computer software. It has two businesses, software and services, which are further divided into five segments. Its software business consist of two segments: The new software license segment is engaged in the licensing of database, middleware software and applications software.The software license updates and product support segment provides customers with rights to unspecified software product upgrades and maintenance releases, internet access to technical content, internet and telephone access to technical support personnel. Its services business is comprised of three segments: The consulting segment provides services in business strategy and analysis, business process simplification, solutions integration and the implementation, enhancement and upgrade of database, middleware and applications software. On Demand includes Oracle On Demand and Advanced Customer Services.

Oracle Corp.

Oracle is currently a focal point for retail investors, with intense community debate centered on whether its aggressive debt-fueled expansion and massive AI infrastructure buildout represent a deep-value opportunity or an overleveraged disaster. While bullish investors point to emerging government contracts and a vast backlog as catalysts for a rebound, many participants are expressing skepticism, labeling the recent volatility as extreme market manipulation and warning of further downside risks.

Atai Beckley, Inc. is a clinical-stage biopharmaceutical company focused on developing effective, rapid-acting, and convenient mental health treatments. The company is headquartered in New York, NY.

AtaiBeckley Inc.

ATAI is trending as investors react to the news of its acquisition by Eli Lilly for an upfront cash payment plus milestone-based contingent value rights. While the psychedelic biotech community debates the deal's valuation, active discussions are focused on the long-term impact of Big Pharma entering the sector, potential alternative counterbids, and the implications for existing shareholders.

Marvell Technology, Inc. engages in the design, development, and sale of integrated circuits. Its products include data processing units, security solutions, automotive, coherent DSP, DCI optical modules, ethernet controllers, ethernet PHYs, ethernet switches, linear driver, PAM DSP, transimpedance amplifiers, fibre channel, HDD, SSD controller, storage accelerators, ASIC, and Marvell government solutions. It operates through the following geographical segments: United States, Singapore, Israel, India, China, and Others. The company was founded by Wei Li Dai and Pantas Sutardja in 1995 and is headquartered in Wilmington, DE.

Marvell Technology Inc

Marvell Technology is trending as investors aggressively reassess the stock's valuation following a steep pullback from recent highs, with sentiment split between those viewing the decline as a buying opportunity in the custom AI silicon leader and those fearing a broader unwind of AI-related momentum. The community is actively debating the stock's technical support levels and the sustainability of its growth narrative, with significant focus on institutional positioning and the long-term impact of AI infrastructure demand.

AST SpaceMobile, Inc. engages in building a broadband cellular network in space to operate directly with standard, unmodified mobile devices based on an intellectual property and patent portfolio. It focuses on providing mobile broadband services with global coverage to all end-users, without the need to purchase special equipment. The company was founded by Abel Avellan on May 31, 2017 and is headquartered in Midland, TX.

AST SpaceMobile Inc - Ordinary Shares - Class A

AST SpaceMobile Inc

AST SpaceMobile is facing significant downward pressure following an announcement of a $1 billion convertible senior note offering intended to fund network deployment and secure orbital access. While management frames the capital raise as a strategic move to accelerate satellite infrastructure, the community is sharply divided, with many investors expressing frustration over perceived contradictions regarding previous capital guidance and the timing of the dilution.

Compass Pathways Plc is a biotechnology company, which provides mental health care services. It focuses on improving the lives of those who are suffering with mental health challenges and who are not helped by current treatments. The company was founded by Goldsmith George Jay and Malievskaia Ekaterina in 2016 and is headquartered in London, the United Kingdom.

Compass Pathways Plc - ADR

COMPASS Pathways

COMPASS Pathways is currently in the spotlight as investors anticipate major phase 3 clinical data, with the stock recently showing resilience despite broader market volatility. The community is heavily focused on the company's first-mover advantage and strong clinical progress, drawing comparisons to recent successful sector acquisitions and pending FDA guidance as key indicators of long-term sector validation.

PayPal Holdings, Inc. engages in the development of technology platforms that enable digital payments and simplifies commerce experiences on behalf of merchants and consumers worldwide. Its solutions include PayPal, PayPal Credit, Braintree, Venmo, Xoom, and Paydiant products. The firm also enables consumers to exchange funds with merchants using funding sources, which include bank account, PayPal account balance, PayPal Credit account, credit, and debit card or other stored value products. It operates through United States and Other Countries geographical segments. The company was founded in December 1998 and is headquartered in San Jose, CA.

PayPal Holdings Inc

PayPal is surging following reports that Stripe and Advent International have submitted a takeover bid valuing the company at roughly $53 billion. Investors are actively debating whether this initial offer significantly undervalues the firm's robust cash flow and long-term potential, fueling widespread speculation about a possible bidding war.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Castle Biosciences Announces New York State Department of Health Approval of its AdvanceAD-Tx Test

Castle Biosciences Announces New York State Department of Health Approval of its AdvanceAD-Tx Test Castle Biosciences Announces New York State Department of Health Approval of its AdvanceAD-Tx Test PR Newswire FRIENDSWOOD, Texas, July 14, 2026 Approval expands access to Castle's precision medicine...

Castle Biosciences to Release Second Quarter 2026 Financial Results and Host Webcast on Thursday, July 30, 2026

Castle Biosciences to Release Second Quarter 2026 Financial Results and Host Webcast on Thursday, July 30, 2026 Castle Biosciences to Release Second Quarter 2026 Financial Results and Host Webcast on Thursday, July 30, 2026 PR Newswire FRIENDSWOOD, Texas, July 9, 2026 FRIENDSWOOD, Texas, July 9...

DecisionDx-Melanoma's i31-SLNB Outperforms MIA Nomogram in Identifying Patients Who May Safely Forgo Sentinel Lymph Node Biopsy

DecisionDx-Melanoma's i31-SLNB Outperforms MIA Nomogram in Identifying Patients Who May Safely Forgo Sentinel Lymph Node Biopsy DecisionDx-Melanoma's i31-SLNB Outperforms MIA Nomogram in Identifying Patients Who May Safely Forgo Sentinel Lymph Node Biopsy PR Newswire FRIENDSWOOD, Texas, June 25...

Castle Biosciences' Chief Financial Officer Frank Stokes Named a 2026 CFO Awards Honoree by the Houston Business Journal

Castle Biosciences' Chief Financial Officer Frank Stokes Named a 2026 CFO Awards Honoree by the Houston Business Journal Castle Biosciences' Chief Financial Officer Frank Stokes Named a 2026 CFO Awards Honoree by the Houston Business Journal PR Newswire FRIENDSWOOD, Texas, June 23, 2026 Stokes was...

Castle Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Castle Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Castle Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PR Newswire FRIENDSWOOD, Texas, June 19, 2026 FRIENDSWOOD, Texas, June 19, 2026 /PRNewswire/ -- Castle Biosciences, Inc. (Nasdaq...

Castle Biosciences' TissueCypher Test Surpasses 100,000 Orders, Advancing Precision Risk Assessment for Patients with Barrett's Esophagus

Castle Biosciences' TissueCypher Test Surpasses 100,000 Orders, Advancing Precision Risk Assessment for Patients with Barrett's Esophagus Castle Biosciences' TissueCypher Test Surpasses 100,000 Orders, Advancing Precision Risk Assessment for Patients with Barrett's Esophagus PR Newswire...

Castle Biosciences' AdvanceAD-Tx Test Receives 2026 MedTech Breakthrough Award for Genomics Innovation

Castle Biosciences' AdvanceAD-Tx Test Receives 2026 MedTech Breakthrough Award for Genomics Innovation Castle Biosciences' AdvanceAD-Tx Test Receives 2026 MedTech Breakthrough Award for Genomics...

Castle Biosciences (NASDAQ:CSTL) Releases Earnings Results, Hits Expectations

Castle Biosciences (NASDAQ:CSTL - Get Free Report) posted its quarterly earnings data on Wednesday. The company reported ($0.49) earnings per share for the quarter, hitting analysts' consensus estimates of ($0.49). The company had revenue of $84.23 million during the quarter, compared to analysts...

Castle Biosciences Q1 Earnings Call Highlights

Castle Biosciences (NASDAQ:CSTL) reported first-quarter 2026 revenue of $83.7 million, supported by continued growth in what management described as its "core revenue drivers," DecisionDx-Melanoma and TissueCypher. Founder, President and CEO Derek Maetzold said test report volumes for the company's...

Castle Biosciences, Inc. (CSTL) Reports Q1 Loss, Beats Revenue Estimates

Castle Biosciences (CSTL) delivered earnings and revenue surprises of +12.50% and +2.65%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

Castle Biosciences, Inc. is a molecular diagnostics company, which offers innovative test solutions to aid clinicians in the diagnosis and treatment of dermatologic cancers, barrett’s esophagus, uveal melanoma, and in the treatment of mental health conditions. The firm offers DecisionDx-Melanoma, a proprietary multi-gene expression profile (GEP) test that predicts the risk of metastasis and recurrence for patients diagnosed with invasive cutaneous melanoma. It also markets DecisionDx-UM, Decision Dx DiffDx-Melanoma, DecisonDx-CMSeq, DecisionDx-SCC, DecsionDx-UMSeq, and DecisonDX-PRAME. The company was founded by Derek J. Maetzold in September 2007 and is headquartered in Friendswood, TX.

Castle Biosciences Inc

Neutral Sentiment

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Fiscal Period	Estimated	Reported	Surprise	Result
Q2 '26	-$0.41	--	--	N/A
Q1 '26	-$0.49	-$0.49	--	EXPECTED
Q4 '25	-$0.26	-$0.08	69.07%	BEAT
Q3 '25	-$0.52	-$0.02	96.16%	BEAT
Q2 '25	-$0.53	$0.15	128.24%	BEAT

Feed

News

Sentiment

Earnings

Fundamentals

Info

CSTLCastle Biosciences Inc

Upcoming Earnings: Q2 '26

Historical Earnings

Latest CSTL News